Carla Grandori

BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Carla Grandori, MD, PhD eRA COMMONS USER NAME (credential, e.g., agency login): cgrandor POSITION TITLE: CEO SEngine Precision Medicine EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) INSTITUTION AND LOCATION DEGREE (if applicable) Completion Date MM/YYYY FIELD OF STUDY Liceum G.B. Vico, Rome, Italy MSc 07/1976 Scientific Study School of Medicine, University of Rome, Italy MD 07/1982 Medicine The Rockefeller University, New York, NY PhD 05/1989 Molecular Biology A. Personal Statement As CEO/CSO of SEngine Precision Medicine, my goal is to apply the most up to date robotics technologies and cancer knowledge to develop novel targeted drugs based on synthetic lethality and match current and future treatments to individual patients. My lifetime career starting with medicine and subsequently as a cancer researcher has been driven by the goal of discovering less toxic, targeted, and potentially curative treatments for cancer. I was fortunate to train with founders of the oncogene field, first Dr. Hanafusa, at the Rockefeller University and later Dr. Eisenman at the Fred Hutchinson Cancer Research Center (FHCRC). My work largely focused on biochemical and molecular biology of tyrosine kinase oncogenes as well as on transcription factors cancer genes, such as MYC. As I established my laboratory, I transitioned into more translational focused research specifically on cancers where MYC plays an important role, neuroblastoma and ovarian cancer, later expanded through a key MYC pan-cancer study, which I led together with The Cancer Genome Atlas team. These experiences laid the foundation toward identifying novel candidate drug targets based on the concept of synthetic lethality. My academic background has been enriched by experience in the industry setting, Rosetta Inpharmatics, a subsidiary of Merck, where novel oncology drugs were evaluated using high-throughput technology and bioinformatics. This experience was essential for my establishment and directing of the Quellos High Throughput Screening (HTS) core at the University of Washington, among the first of its kind in an academic setting. The success of this enterprise that was recognized by the University with a Presidential Entrepreneurial Award. In response to direct requests from cancer patients my career then took a sharp twist. In 2012 I founded Cure First, a not-for-profit 501c3 organization dedicated to supporting functional genomics approaches using Automated RNA Interference Array (ARIA) to accelerate the discovery of drug targets and novel drug combinations. In 2015 I co-founded SEngine Precision Medicine to develop a commercial test to personalize treatments and increase the efficiency of drug development using organoid-based testing. At SEngine we strive to provide the most comprehensive and accurate drug sensitivity testing to help oncologists select personalized cancer treatments for their patients. With this goal, we have established the first CLIA-certified laboratory in the US to provide a clinically useful report integrating genomics and functional screening for solid tumors. As outlined in the current proposal, this platform provides the basis to establish a diagnostic assay based on colon cancer to personalize treatments in the context of future clinical trials. In summary I am uniquely qualified to ensure this Academic Industry Partnership leads to widespread adoption of the PARIS assay for cancer patients. • Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling, BE, Gadi, VK, Bernard, B, Elemento, O Beltran H, Dimichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA (2017) Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discovery, 7(5); 462–77, 2017. • Scuoppo C, Wang J, Persaud M, Mittan SK, Basso K, Pasqualucci L, Rabadan R, Inghirami G, Grandori C, Bosch F, Dalla-Favera R. Repurposing dasatinib for diffuse large B cell lymphoma. Proc. Nat. Acad. Sci. 2019; 116(34):16981-16986. PubMed PMID: 31383760; PubMed Central PMCID: PMC6708382. • Narasimhan V, Wright JA, Churchill M, Wang T, Rosati R, Lannagan TRM, Vrbanac L, Richardson AB, Kobayashi H, Price T, Tye GXY, Marker J, Hewett PJ, Flood MP, Pereira S, Whitney GA, Michael M, Tie J, Mukherjee S, Grandori C, Heriot AG, Worthley DL, Ramsay RG, Woods SL. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clin. Cancer Res. 2020, 26 (14): 3662–3670, PMID: 32376656. • Shigeta, S.